These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11115054)

  • 1. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.
    Wolters LM; van Nunen AB; Honkoop P; Vossen AC; Niesters HG; Zondervan PE; de Man RA
    J Viral Hepat; 2000 Nov; 7(6):428-34. PubMed ID: 11115054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B with flare due to co-infection of hepatitis delta virus during lamivudine therapy.
    Joh R; Hasegawa K; Tokushige K; Hashimoto E; Torii N; Yamashiro T; Enomoto N; Watanabe M; Hayashi N
    Intern Med; 2003 Jul; 42(7):581-6. PubMed ID: 12879950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
    Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
    Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
    Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
    Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine for chronic delta hepatitis.
    Lau DT; Doo E; Park Y; Kleiner DE; Schmid P; Kuhns MC; Hoofnagle JH
    Hepatology; 1999 Aug; 30(2):546-9. PubMed ID: 10421666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.
    Sprengers D; van der Molen RG; Binda R; Kusters JG; de Man RA; Niesters HG; Schalm SW; Janssen HL
    J Viral Hepat; 2007 Oct; 14(10):743-9. PubMed ID: 17875010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.
    Spaan M; Carey I; Bruce M; Shang D; Horner M; Dusheiko G; Agarwal K
    J Hepatol; 2020 Jun; 72(6):1097-1104. PubMed ID: 31981726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.